WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 401515
Description: KCN1, a novel synthetic sulfonamide, is a HIF pathway inhibitor with potential anticancer activity in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. KCN1 specifically inhibited HIF reporter gene activity in several glioma cell lines at the nanomolar level. KCN1 also downregulated transcription of endogenous HIF-1 target genes, such as VEGF, Glut-1, and carbonic anhydrase 9, in a hypoxia-responsive element (HRE)-dependent manner. KCN1 potently inhibited the growth of subcutaneous malignant glioma tumor xenografts with minimal adverse effects on the host.
MedKoo Cat#: 401515
Chemical Formula: C26H27NO5S
Exact Mass: 465.16099
Molecular Weight: 465.56
Elemental Analysis: C, 67.08; H, 5.85; N, 3.01; O, 17.18; S, 6.89
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: KCN1; KCN-1; KCN 1.
IUPAC/Chemical Name: 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide
InChi Key: IPZJNJPAVPZHJM-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H27NO5S/c1-26(2)15-14-20-16-19(10-12-23(20)32-26)18-27(21-8-6-5-7-9-21)33(28,29)22-11-13-24(30-3)25(17-22)31-4/h5-17H,18H2,1-4H3
SMILES Code: O=S(C1=CC=C(OC)C(OC)=C1)(N(CC2=CC(C=CC(C)(C)O3)=C3C=C2)C4=CC=CC=C4)=O
Appearance: Solid powder
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 465.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13. PubMed PMID: 23028659; PubMed Central PMCID: PMC3441526.
2: Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z, Boreddy PR, Wang W, Wang Z, Abbruscato T, Chen Z, Olson JJ, Zhang R, Goodman MM, Nicolaou KC, Van Meir EG. Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP. Clin Cancer Res. 2012 Nov 21. [Epub ahead of print] PubMed PMID: 22923450; PubMed Central PMCID: PMC3518680.
The following data was from PLoS One . 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13.
Figure 1. In vitro anticancer activities of KCN1 against pancreatic cancer cells. (B) Cell growth inhibitory activity of KCN1 in human pancreatic cancer cells. Cells were exposed to various concentrations of KCN1 for 72 h, followed by an MTT assay. ( Source: PLoS One . 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13. )
Figure 1. In vitro anticancer activities of KCN1 against pancreatic cancer cells. (B) Cell growth inhibitory activity of KCN1 in human pancreatic cancer cells. Cells were exposed to various concentrations of KCN1 for 72 h, followed by an MTT assay. (